Zhitong Finance App learned that innovative drug concept stocks rose collectively. As of press release, Zaiding Pharmaceutical (09688) rose 13.40% to HK$20.82; Kingsley Biotech (01548) rose 6.06% to HK$32.22; Conoa-B (02162) rose 5.63% to HK$73.2; and Kangfang Biotech (09926) rose 5.22% to HK$89.7.

According to the news, listed companies have successively disclosed their third-quarter results, and a number of innovative pharmaceutical companies have achieved both revenue and net profit growth. According to Huafu Securities, 27 A-share Biopharma and Biotech companies achieved revenue of 73.2 billion yuan in the first three quarters of 2026, an increase of 45% over the previous year, and achieved a total net profit of 16.6 billion yuan to mother, an increase of 1326.5% over the previous year.

Looking at the third quarter alone, we achieved revenue of 28.6 billion yuan, a year-on-year increase of 46.4%, and net profit to mother of 8.91 billion yuan, an increase of 870.9% over the previous year. The bank pointed out that the sector has been profitable for 5 consecutive quarters since 2025Q3, and the 26Q3 single quarter's profit reached a record high. 2026-2027 is expected to usher in an intensive period of turning losses into profits for outstanding innovative pharmaceutical companies.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.